The future of dynamic blood glucose monitoring in the innovative series of pharmaceutical companies

[China Pharmaceutical Network Technology News] According to media reports, Bayer cooperated with the China Red Cross Foundation Chronic Care Fund and the Education Management Group of the Chinese Medical Association Diabetes Branch to launch the “Power China Postprandial Blood Glucose Optimization Management Platform Project”, the project It will be the main means of optimizing post-prandial blood glucose management in the national general hospital, health education consultation classroom, and guiding patients to scientific self-management. It aims to help type 2 diabetes through multi-party cooperation and popularization of postprandial postprandial blood glucose optimization control knowledge. Patients, especially newly diagnosed diabetic patients, undergo a standardized professional post-prandial glycemic management.

As an old Bayer who has fought with Bai Tangping for 8 years, I saw that the old club started to use the new Internet means to manage diabetes. It seems that the mood can be expressed as joy and blessing.

In the past, Bai Tangping talked about "eliminating peaks and going to the valley" for many years. The meaning is that Bai Tangping has a very good effect in reducing blood sugar fluctuations, especially when combined with insulin. It can reduce the amount of insulin (to avoid some bad effects of long-term use of insulin). Reaction) can reduce the occurrence of hypoglycemia.

The most important monitoring method of “eliminating peaks and going to the valley” is dynamic blood glucose monitoring (CGM). We review the history of blood glucose monitoring technology. Traditional blood glucose monitoring methods have different limitations. 1. Self-glycemic monitoring is blood glucose monitoring. The basic form, but the point of blood glucose reflects the instantaneous blood sugar changes, can not fully reflect the patient's full-day blood glucose value, there is monitoring "blind area"; 2, glycosylated hemoglobin (HbA1c) is the gold standard reflecting long-term (2 ~ 3 months) blood sugar control However, there is a "delay effect" in the assessment of post-treatment adjustments and does not reflect the risk of hypoglycemia and the characteristics of blood glucose fluctuations. CGM is an effective supplement to traditional blood glucose monitoring methods. If the traditional blood glucose monitoring method is like a "camera", then CGM can be called a "recorder". CGM can provide a comprehensive blood glucose log, including 288 blood glucose values ​​per day. Daily blood glucose map, multi-day blood glucose map, specific time blood glucose map, and blood glucose graph summary with blood glucose fluctuations, mean, mean absolute difference, correlation coefficient, pie chart, and area under the blood glucose curve. Through the blood glucose curve provided by CGM, various problems such as nocturnal hypoglycemia can be found at a glance, and it is also helpful to identify "occult" hypoglycemia and hyperglycemia.

About Dynamic Blood Glucose Monitoring (CGM)

The evaluation of the therapeutic effect of CGM and the effect of insulin therapy on blood glucose fluctuations found that the blood glucose fluctuation level of normal glucose regulators was negatively correlated with the early phase insulin secretion function, indicating that the islet function was relatively poor, and the islet function was relatively poor. Intensive insulin therapy for type 2 diabetes can reduce blood glucose fluctuations by 30% to 40%. The confirmation of the effect of a number of oral hypoglycemic agents on blood glucose fluctuations, although common oral drugs such as acarbose and monotherapy for type 2 diabetes can significantly reduce blood sugar fluctuations, but the combination of treatment for blood sugar fluctuations is more significant. This is also the essence of Bai Tangping's “eliminating the peaks and going to the valley”.

Since CGM is an effective complement to traditional blood glucose monitoring methods, even from the perspective of accurate data collection and analysis far beyond the meaning of “point blood glucose” monitoring, what is the latest development of CGM itself in this era of data medical practice? ?

Global CGM development enters the digital age

Senseonics, a Maryland-based manufacturer of continuous blood glucose monitoring equipment, is Eversense, which has less trauma and lasts longer than previous CGM devices and is currently not FDA-approved and CE certified. In early 2016, the company submitted an IPO and is currently aggressively promoting partnerships with potential users to maximize the user experience of their devices and establish a path to send user data to healthcare providers.

Senseonics recently announced a partnership with Diasend, a diabetes data management company in Sweden. Diasend collects data from a number of different devices, including blood glucose meters, CGM systems and insulin pumps, and sends the data to an Apple or Android phone application. Diasend also sends the preparation report to the clinician. Application integration behavior tracking allows users to assess their blood glucose levels and their relationship to exercise.

“We believe that turning data from CGM and pumping equipment into actionable data is very important to users,” Dr. Tim Goodnow, CEO and CEO of Senseonics, said in a statement. “The goal of Eversence's CGM system is to help people with diabetes spend less time managing their devices and more time managing their diabetes.... Senseonics must work with a valued partner like Diasend, Diasend has The well-known diabetes community gives users access to more historical data and more comprehensive data management solutions."

Senseonics fully implants a pill-sized sensor into the user's upper arm to continuously monitor their blood sugar levels. The device's continuous working time is 90 days, and the current use of similar devices is 5 to 7 days. The sensor sends the data to a transmitter that the user wears on the upper arm. When the user is in use, the data transmitter can take the readings from the implanted sensors and send them to a companion smartphone app. The transmitter can also upload blood glucose history data to the computer via USB.

Diasend began working with Dexcom in the fall of 2015 to integrate with the Dexcom G5 Mobile CGM. Dias end's scope of cooperation is very broad, including Dexcom, Abbott, Roche, Bayer, Sanofi, etc. However, so far, there is no cooperation with any Medtronic equipment.

Both Sensionics and Diasend are targeting Europe as the initial market for their integration, and it is worth noting that the Diasend platform is FDA-approved. Therefore, if Senseonics is approved by the FDA, its integration platform will easily occupy the US market.

Author: Archimedes medical horse today